Clinical trial
A Dose Finding Phase I Trial of the Combination of Topotecan and PS-341, a Novel…
NCT00068484 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00068484 |
|---|---|
| Title | A Dose Finding Phase I Trial of the Combination of Topotecan and PS-341, a Novel Proteasome Inhibitor, in Advanced Malignancies |
| Official title | A Dose Finding Phase I Trial of the Combination of Topotecan and PS-341, a Novel Proteasome Inhibitor, in Advanced Malignancies |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug, Other |
| Interventions | topotecan hydrochloride, bortezomib, pharmacological study, laboratory biomarker analysis |
| Enrollment | 25 |
| Start date | Jul 1, 2003 |
| Primary completion | Feb 1, 2006 |
| First posted | Sep 11, 2003 |
| Last update posted | Feb 1, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: